March 31, 2025 03:06 PM EDTUpdated 03:19 PM

FDA sets new date for opioid-focused advisory meeting after earlier delay

Max Bayer

Pharma Reporter

A meeting of outside experts to discuss the FDA’s post-marketing requirements for opioid medications is now slated for May 5 after being postponed earlier this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA sets new date for opioid-focused advisory meeting after earlier delay

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

FDA sets new date for opi­oid-fo­cused ad­vi­so­ry meet­ing af­ter ear­li­er de­lay

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

FDA sets new date for opioid-focused advisory meeting after earlier delay

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO